Skip to main content

Table 3 Results of linear regression analyses

From: Association of CYP2D6metabolizer status with mammographic density change in response to tamoxifen treatment

   Univariate Adjusted
  n Beta SE Pwald Ptrend Pnptrend Beta SE Pwald Ptrend
PMD change (continuous)*
  EM 122 0.00 Reference 0.053 0.074 0.00 Reference 0.11
  hetEM/IM 136 1.47 0.78 0.06    0.87 0.67 0.19  
  PM 20 1.89 1.51 0.21    1.61 1.29 0.21  
Adjusted R2      0.010      0.281
Baseline PMD†
  EM 122 0.00 Reference 0.389 0.301 0.00 Reference 0.771
  hetEM/IM 136 -0.24 0.17 0.16    -0.17 0.15 0.29  
  PM 20 0.00 0.33 1.00    0.11 0.30 0.72  
Adjusted R2      0.001      0.162
Follow-up PMD†
  EM 122 0.00 Reference 0.831 0.999 0.00 Reference 0.413
  hetEM/IM 136 -0.07 0.15 0.64    -0.02 0.14 0.90  
  PM 20 0.23 0.30 0.44    0.31 0.28 0.27  
Adjusted R2      -0.003      0.100
  1. Results of linear regression analyses treating the absolute difference between follow-up and baseline values in percent mammographic density (PMD) as a continuous variable, and PMD at baseline and follow-up separately. PMD at baseline or follow-up was square-root transformed. *Adjusted for baseline percent mammographic density (PMD), age at baseline (years), and body mass index at baseline (kg/m2). †Adjusted for all of the above except for baseline PMD. SE, standard error; Pwald, P value from Wald tests; Ptrend, P value from Wald tests treating genotypes (0, 1, 2) as a continuous variable; Pnptrend, P value from Cuzick’s test for trend; EM, extensive metabolizer; hetEM/IM, heterozygous extensive/intermediate; PM, poor metabolizer; adjusted R2, adjusted R2 statistic.